ZYUS LIFE SCIENCES CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.11 CAD | +2.78% |
|
+8.82% | +23.33% |
| Sales 2024 * | 428K 314K | Sales 2025 * | - | Capitalization | 76.52M 56.15M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 179 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 41.92% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.78% | ||
| 1 week | +8.82% | ||
| Current month | +2.78% | ||
| 1 month | +5.71% | ||
| 3 months | +13.27% | ||
| 6 months | +11.00% | ||
| Current year | +23.33% |
1 week
0.95
1.11
1 month
0.951.19
Current year
0.841.19
1 year
0.711.41
3 years
0.711.41
5 years
0.711.41
10 years
0.711.41
| Managers | Title | Age | Since |
|---|---|---|---|
Brent Zettl
FOU | Founder | 61 | 18-03-31 |
John Hyshka
DFI | Director of Finance/CFO | - | - |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wayne Brownlee
BRD | Director/Board Member | 71 | 23-06-28 |
John Knowles
BRD | Director/Board Member | 68 | 20-08-31 |
Brent Zettl
FOU | Founder | 61 | 18-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-03 | 1.11 | +2.78% | 3 900 |
| 24-05-31 | 1.08 | +5.88% | 1,000 |
| 24-05-30 | 1.02 | +0.99% | 1,300 |
| 24-05-29 | 1.01 | -0.98% | 3,300 |
| 24-05-28 | 1.02 | 0.00% | 1,000 |
Delayed Quote Toronto S.E., June 03, 2024 at 09:33 am EDT
More quotes
ZYUS Life Sciences Corporation is a Canada-based life sciences company. The Company is focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and exempt market therapeutics. Through clinical research, it is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, the Company delivers cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The Company is also focused on commercialization of its exempt market therapeutics, such as cannabinoid oils, soft gel capsules and topical creams, in Canada and those international markets where medical cannabis is legal.
Calendar
2024-06-27
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.08
CAD
Average target price
2.75
CAD
Spread / Average Target
+154.63%
| 1st Jan change | Capi. | |
|---|---|---|
| +23.33% | 56.08M | |
| +51.13% | 54.63B | |
| -4.95% | 39.92B | |
| +37.60% | 38.82B | |
| +15.49% | 26.86B | |
| -12.56% | 26.22B | |
| -21.61% | 18.78B | |
| +25.32% | 12.21B | |
| +1.97% | 12.16B | |
| +26.93% | 11.94B |
- Stock Market
- Equities
- ZYUS Stock
